Showing 1-11 of 11 results for "141-82-2"
Hyun I Park et al.
The Journal of biological chemistry, 277(38), 35168-35175 (2002-07-18)
Human endometase/matrilysin-2/matrix metalloproteinase-26 (MMP-26) is a novel epithelial and cancer-specific metalloproteinase. Peptide libraries were used to profile the substrate specificity of MMP-26 from the P4-P4' sites. The optimal cleavage motifs for MMP-26 were Lys-Pro-Ile/Leu-Ser(P1)-Leu/Met(P1')-Ile/Thr-Ser/Ala-Ser. The strongest preference was observed at...
M R Rodríguez et al.
Tissue antigens, 59(4), 311-315 (2002-07-24)
The natural resistant-associated macrophage protein 1 (NRAMP1) has been proposed as a candidate gene for the susceptibility to autoimmune diseases. In this study, the possible role of the functional polymorphism located at the promoter region of NRAMP1 gene in the...
Xiao Wang et al.
Radiology, 254(1), 69-78 (2009-12-19)
To evaluate the osteopontin (OPN) protein expression levels in breast carcinomas to determine if they correlate with mammographic appearances such as calcifications. This retrospective study was institutional review board approved. Informed consent was obtained from patients. Clinical history, histopathologic findings...
Daniela Lixandru et al.
Annals of nutrition & metabolism, 56(4), 294-301 (2010-05-11)
The antiatherosclerotic enzyme paraoxonase (PON1) is affected by disease and lifestyle. We investigated the impact of diet in diabetic foot patients from 2 European countries. Dietary intake and serum PON1 activity, using as substrate paraoxon (paraoxonase) or phenylacetate (arylesterase), were...
Jozsef Czimmer et al.
Current pharmaceutical design, 19(1), 11-16 (2012-09-07)
Cytokines are known to play a key role in regulation of gastric functions. Interferon-alpha (IFN-α) has been published to impair gastric motility. Aims of this study were to clarify effect of IFN-α on gastric acid secretion (GAS) and determine role...
Nigel J Bundred et al.
Breast cancer research : BCR, 14(1), R13-R13 (2012-01-19)
The Livial Intervention Following Breast Cancer: Efficacy, Recurrence and Tolerability Endpoints (LIBERATE: Clinical number NCT00408863), a randomized, placebo-controlled, double-blind trial that demonstrated that tibolone (Livial), a tissue-selective hormone-replacement therapy (HRT), increased breast cancer (BC) recurrence HR 1.40 (95% CI...
Song Ee Han et al.
International journal of oncology, 24(2), 435-440 (2004-01-14)
Caveolin-1, a tumor suppressor gene, was found to be inactivated by structural abnormalities or epigenetic changes in several types of human cancers. In order to investigate the role of Caveolin-1 in the pathogenesis of human oral squamous cell carcinoma, the...
Tilman T Zittel et al.
Diseases of the colon and rectum, 56(6), 761-767 (2013-05-09)
Cyclo-oxygenase 2 inhibitors can be used for pain treatment after colorectal surgery. The aim of this study was to investigate whether the use of etoricoxib has negative effects on the perioperative outcome in colorectal surgery. Complication data from an advanced...
Carmen A Peralta et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 60(6), 904-911 (2012-07-04)
Whether elevations in levels of urinary biomarkers of tubular injury (urine neutrophil gelatinase-associated lipocalin [NGAL] and kidney injury molecule 1 [KIM-1]) are associated with future risk of kidney disease has not been investigated. 1:1 nested case-control study. 686 participants in...
Alcides Chaux et al.
The American journal of surgical pathology, 34(3), 385-392 (2010-02-09)
From the pathogenic point of view, penile cancers may be grouped in human papillomavirus-related and unrelated tumors, each one of them with distinctive morphologic features. The former are predominantly composed of small, undifferentiated basaloid cells, with more or less prominent...
Gunter von Minckwitz et al.
The Lancet. Oncology, 15(7), 747-756 (2014-05-06)
Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, trastuzumab, and a platinum salt for HER2-positive breast cancer. We therefore aimed to assess the efficacy...

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.